Skip to main content

Cancer News (Page 18)

Related terms: Carcinoma, Malignant Disease, Malignant Tumor

Report Highlights Big Gaps in Cancer Outcomes Based on Race

WEDNESDAY, May 15, 2024 – U.S. cancer death rates are continuing to drop, falling by 33% between 1991 and 2020. However, not all Americans are reaping the benefits from advances in cancer...

AACR Delivers Report on Disparities in Cancer Progress

WEDNESDAY, May 15, 2024 – In its biennial Cancer Disparities Progress Report published today, the American Association for Cancer Research presents the latest statistics on disparities in cancer...

Cancer & COVID Drove Him to Double-Lung Transplant

MONDAY, May 13, 2024 – Chicago resident Arthur “Art” Gillespie fell ill in early March 2020 with COVID, after he and his father went to visit an uncle in a nursing facility. “I was hospitalized for 1...

FDA Approves Genentech’s Tecentriq as First-Ever Therapy for a Certain Advanced Rare Sarcoma Called Alveolar Soft Part Sarcoma (ASPS)

South San Francisco, CA – December 9th, 2022 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) for ...

Incyte Announces FDA Approval of Pemazyre (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with...

FDA Approves Lonsurf (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

PRINCETON, N.J., February 25, 2019 – Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved Lonsurf as a treatment for adult patients with m...

FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers

November 26, 2018 – The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific...

FDA Approves Keytruda (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

KENILWORTH, N.J.--(BUSINESS WIRE) October 30, 2018 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...

FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer

November 2, 2018 Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Lorbrena [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma...

FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer

On October 16, 2018, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected...

FDA Approves Opdivo (nivolumab) for Certain Patients with Previously Treated Small Cell Lung Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--August 17, 2018 – Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) received approval from the U.S. Food and Drug Administration (FDA)...

Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer

PRINCETON, N.J.-- July 11, 2018 (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for...

FDA Approves Mektovi (binimetinib) and Braftovi (encorafenib) in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations

On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma Inc.) in combination for patients with unresectable or metastatic...

Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations

BOULDER, Colo., June 27, 2018 /PRNewswire/ – Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi capsules in combination with...

FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

18 April 2018 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Breast Cancer, Prostate Cancer, Colorectal Cancer, Renal Cell Carcinoma, Skin Cancer, Ovarian Cancer, Endometrial Cancer, Lung Cancer, Gastric Cancer

Related drug support groups

fluorouracil